This document can be used to prepare or evaluate feasibility of ancillary study proposals and paper proposals, but is NOT intended for publication.

HRT and CaD Unblindings Prior to Study Closure

File NameData as ofPopulationData collectedOne row perRows
unbl_ct_inv.dat9/12/2005CTMainUnblinding4,801
ID - WHI Participant Common ID
Col 1
NMissing
4,8010
UNBLSTDY - Study for which unblinding occurred
Col 2
ValueDescriptionN%
1HRT Unblinding4,74398.8
2CaD Unblinding581.2
UNBLSEQ - Unblinding sequence within study
Col 3
Unblinding sequence within study for the participant
NMissingMinMaxMeanStdDev
4,8010151.1260.394
UNBLDAYS - Unblinding days since CT randomization
Col 4
NMissingMinMaxMeanStdDev
4,801023,528720.115595.687
UNBCADDY - Unblinding days since CaD randomization
Col 5
NMissingMinMaxMeanStdDev
3,0431,758-7333,155350.859605.242
ADVERSE - Unblinding due to study medication adverse effects
Col 6
ValueDescriptionN%
0No2,59554.1
1Yes2,20645.9
OVERDOSE - Unblinding due to overdose
Col 7
ValueDescriptionN%
0No4,78999.8
1Yes120.2
OTHERMED - Unblinding due to other medical problem
Col 8
ValueDescriptionN%
0No4,03083.9
1Yes77116.1
GYNCNSL - Gynecologist or designated physician consulted
Col 9
ValueDescriptionN%
0No1583.3
1Yes4,64396.7
TREAT - Attempted to treat condition without unblinding
Col 10
ValueDescriptionN%
0No2,83959.1
1Yes1,96240.9
GYNORDER - Order to unblind given by gynecologist/physician
Col 11
Order to unblind given by gynecologist or designated physician
ValueDescriptionN%
0No2595.4
1Yes4,54294.6
PIORDER - Order to unblind given by PI
Col 12
Order to unblind given by Clinical Center Principal Investigator
ValueDescriptionN%
0No3,84280
1Yes95920